Few topics are as buzzed about in healthcare circles as mobile apps.
Everyone’s moving toward smartphones, the population is aging and mobile apps can bring convenience, greater access and cost savings to the health system, according to the prevailing wisdom.
And that’s probably all true.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
But it doesn’t mean venture investors are interested.
One VC who doesn’t expect to jump on the mobile apps bandwagon is Barbara Lubash of Versant Ventures.
“Apps tend to be products with narrow applications and short life cycles,” Lubash said at the American Telemedicine Association‘s annual conference.
Lubash questioned whether an app could be “a sustainable product” because it’s essentially “just an app” and not a technology platform.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
So not only is it difficult for VCs to feel confident in picking a winner in the crowded field of medical mobile apps, but even if they could, the market for any one individual app would likely be too small to justify venture investment.
So what does Lubash look for in a health IT investment? Pretty much the same thing any VC looks for in any investment: a big market, a solution to a big problem faced by key healthcare decision makers and an experienced management team, for starters.
“Health IT is typically taking yesterday’s technology and applying it to healthcare, so the big risk is the market and execution, not the technology,” she said. “That’s why you need an experienced CEO.”
